Privacy Policy

This Web Site is owned by AMAG Pharmaceuticals, Inc. Lexington, Massachusetts, USA (“AMAG”) and operated either by us or by a third party with whom we have contracted to host this website for us. The information provided on this Web Site is for general informational and educational purposes only.

This Site is owned and operated by AMAG Pharmaceuticals, Inc., a Delaware corporation located in Lexington, Massachusetts, USA (“AMAG“, “we“, “us“, or “our“). The information provided on this Site is for general informational and educational purposes only. Please read this Privacy Policy before using the Site or submitting Personal Information to us. This Privacy Policy is part of our Terms of Use Agreement, which is available for review at http://www.amagpharma.com/terms-conditions/.

User Consent

AMAG respects the privacy of the visitors to the Site. This Privacy Policy is intended to inform you of our policies and practices regarding the collection, use, and disclosure of any Personal Information you submit to us through the Site. By submitting Personal Information through the Site, you agree to the terms of this Privacy Policy and you expressly consent to the processing of your Personal Information according to this Privacy Policy. BY VIEWING AND ACCESSING THE AMAG WORLD WIDE WEB SITE, WWW.AMAGPHARMA.COM WEBSITE, OR ANY OF OUR WEB SITES, INCLUDING WITHOUT LIMITATION WWW.FERAHEME.COM, WWW.AMAGPHARMAUSA.COM, WWW.IDANEMIA.COM, WWW.LUMARAHEALTH.COM, WWW.GROWTHYOUCANTSEE.COM, and WWW.IRONMATTERS.COM, (EACH A “SITE” or “Web Site“), YOU (“YOU” OR “YOUR“) REPRESENT THAT YOU HAVE READ AND UNDERSTOOD THIS ENTIRE PRIVACY POLICY (“PRIVACY POLICY“) AND YOU AGREE TO ALL THE TERMS OF THIS PRIVACY POLICY. IF YOU DO NOT CONSENT TO THIS PRIVACY POLICY IN ITS ENTIRETY, YOUR SOLE AND EXCLUSIVE REMEDY IS TO IMMEDIATELY CEASE USE OF THE SITE.

A Note about Children

AMAG does not intend to collect personally identifiable information from children under 18 years old. At any time, any person (including the parent or guardian of such child whose information was provided to AMAG) aware of AMAG having been provided personally identifiable information of a child under the age of 18 may contact us at LegalDept@amagpharma.com.

A Note to Users Outside of the United States

This Site is not intended for use by individuals who are not residents of the United States. Your Personal Information may be processed in the country in which it was collected and in other countries, including the United States, where laws regarding processing of Personal Information may be less stringent than the laws in your country. By providing information to us, you acknowledge that we operate in the United States and agree to (i) permit us to transmit and use your Personal Information anywhere necessary, including across international boundaries, to affect the services and transactions provided by AMAG, and (ii) that such use by us shall be subject to the terms and conditions stated in this Privacy Policy.

Types of Data We Receive

We collect Personal Information and Anonymous Data from you when you visit our site and when you send us information or communications. “Personal Information” means data that allows someone to identify or contact you, including, for example, your name, address, telephone number, e-mail address, as well as any other non-public information about you that is associated with or linked to any of the foregoing data such as your gender and nationality. “Anonymous Data” means data that is not associated with or linked to your Personal Information; Anonymous Data does not permit the identification of individual persons. We collect Personal Information and Anonymous Data, as described below.

We collect Personal Information from you, such as first and last name, gender, e-mail and mailing addresses, telephone number, as well as gender and nationality when you sign up for certain newsletters, updates or request certain information from us. This is information that you choose to provide to us. You are not required to provide such Personal Information to us, but if you do not we may not send you certain information.

We may also receive Personal and/or Anonymous Data about you from other sources like telephone or fax, or from companies that provide our products or services by way of a co-branded or private-labeled website or companies that offer their products and/or services on our website (“Third Party Companies”). We may add this information to the information we have already collected from you via our website in order to improve the products and services we provide.

Information Collected via Technology

To make our Site more useful to you, our servers (which may be hosted by a third party service provider) collect information from you, including browser type, operating system, Internet Protocol (IP) address (a number that is automatically assigned to your computer when you use the Internet, which may vary from session to session), domain name, and/or a date/time stamp for your visit. Some of this may be Personal Information and some may be Anonymous Data. AMAG also uses customized software, which may include software that passively collects certain data about your visits to the Site, such as your IP address, the browser version your computer is operating and the time of day you access the Site.

We also may use Cookies (as defined below) or similar technologies and navigational data like Uniform Resource Locators (URL) to gather information regarding the date and time of your visit and the solutions and information for which you searched and which you viewed. Like most websites, we automatically gather this information and store it in log files each time you visit our website or access your account on our network. “Cookies” are small pieces of information that a website sends to your computer’s hard drive while you are viewing a web site. We may use both session Cookies (which expire once you close your web browser) and persistent Cookies (which stay on your computer until you delete them) to provide you with a more personal and interactive experience on our website. Persistent Cookies can be removed by following Internet browser help file directions. If you choose to disable Cookies, some areas of our website may not work properly. Further general information about cookies and how they work is available at www.allaboutcookies.org.

We may allow selected third parties to place cookies through the Site to provide us with better insights into the use of the Site or user demographics or to provide relevant advertising to you. These third parties may collect information about a consumer’s online activities over time and across different websites when he or she uses our website. We may also permit third party service providers to place cookies through our Site to perform analytic or marketing functions where you are notified of them and you have consented to the usage. We do not control the use of such third party cookies or the resulting information and we are not responsible for any actions or policies of such third parties.

We do not use technology that recognizes a “do-not-track” signal from your web browser.

Use of Your Data

  • General Use. In general, Personal Information and Anonymous Data for our general commercial purposes such as to improve our Site, grow our business and to offer our own, our affiliates’ or third-party products or services that we think you may find of interest. For example, we may use your information to respond to requests that you make or to send you additional information about AMAG, such as medical information about a disease state or AMAG product, AMAG investor information, or information about AMAG corporate activities. AMAG reserves the right to reproduce, use, disclose, and distribute Anonymous Data for any purpose.
  • Creation of Anonymous Data. We may create Anonymous Data records from Personal Information by excluding information (such as your name) that makes the data personally identifiable to you. We use this Anonymous Data to analyze request and usage patterns so that we may enhance the content of our Site and services and improve site navigation.
  • Feedback. If you provide feedback on any of our products or related services to us, we may use such feedback for any purpose, provided we will not associate such feedback with your Personal Information. We will collect any information contained in such communication and will treat the Personal Information in such communication in accordance with this Privacy Policy.

Disclosure of Your Personal Information

  • Your Authorization. We may disclose Personal Information if you request or authorize the disclosure.
  • Transactions. We may disclose Personal Information to others in order to help complete a transaction you have requested.
  • Affiliates. We may share Personal Information with our affiliates, in which case we will require our affiliates to honor this Privacy Policy.
  • Corporate Transactions. We may disclose Personal Information as part of a purchase, transfer or sale of services or assets (e.g., in the event that substantially all of our assets are acquired by another party, Personal Information may be one of the transferred assets).
  • Legal Disclosures. We may disclose Personal Information if we believe in good faith that such disclosure is necessary to (a) comply with relevant laws, applicable regulations, governmental and quasi-governmental requests, court orders, or to respond to subpoenas or warrants served on AMAG; or (b) enforce our Terms of Use or other agreements, or to protect or defend our rights, safety or property or the rights, property or safety of our Site users, product users or others.
  • Disclosure to Third Party Service Providers. We may share your Personal Information with our agents, outside vendors or third party service providers to perform functions on our behalf, including for example, to respond to your inquiries or to send you information about our products. These third party service providers are not permitted to use your Personal Information other than to provide the services requested by us.
  • Disclosure to Third Party Companies. We may enter into agreements with Third Party Companies. A Third Party Company may want access to Personal Information that we collect. As a result, we may disclose your Personal Information to a Third Party Company; however, we will not disclose your Personal Information to Third Party Companies for the Third Party Companies’ own direct marketing purposes, unless you have “opted-in” by following the instructions we provide to allow such disclosure. If you have opted-in to receive e-mail communications from a Third Party Company and later wish to discontinue receipt of these e-mails, please contact the Third Party Company directly to update your preferences. The privacy policies of our Third Party Companies may apply to the use and disclosure of your Personal Information that we collect and disclose to such Third Party Companies. Because we do not control the privacy practices of our Third Party Companies, you should read and understand their privacy policies.
  • Anonymous Data. We may disclose Anonymous Data to our affiliates and third parties for any purpose.

Your Choices Regarding Your Personal Information

We offer you choices regarding the collection, use, and sharing of your Personal Information. We will periodically send you free newsletters and e-mails that directly promote the use of our site or the purchase of our products or services and may contain advertisements for Third Party Companies. When you receive newsletters or promotional communications from us, you may indicate a preference to stop receiving further communications from us and you will have the opportunity to “opt-out” by following the unsubscribe instructions provided in the e-mail you receive or by contacting us directly (please see contact information below). Should you decide to opt-out of receiving future mailings, we may share your e-mail address with third parties to ensure that you do not receive further communications from third parties. Despite your indicated e-mail preferences, we may send you notices of any updates to our Terms of Use or Privacy Policy.

Changes to Personal Information

You can access, update and/or delete your Personal Information by contacting us at the phone number, mailing address or email provided on this website. However, even if you delete or change your Personal Information, it may still be stored on other databases, including those kept for archival purposes. Please also note that we may be required (by law or otherwise) to keep this information and not delete it (or to keep this information for a certain time, in which case we will comply with your deletion request only after we have fulfilled such requirements).

Security of Your Personal Information

We use reasonable technical, administrative and physical measures to protect Personal Information from unauthorized access, use, or disclosure. Even though we have taken steps to protect your Personal Information from being intercepted, accessed, used, or disclosed by unauthorized persons, we cannot fully eliminate security risks associated with Personal Information.

Links to Third Parties’ Sites

The Site may contain links to other websites. AMAG is not responsible for the content or privacy practices of any other “linked” or “affiliated” sites which you might access through our Site. You should read their privacy policies and terms of use carefully before providing them with Personal Information. When you click on such a link, you will leave our site and go to another site. During this process, another entity may collect Personal Information or Anonymous Data from you. We have no control over, do not review, and cannot be responsible for, these outside websites or their content. Please be aware that the terms of this Privacy Policy do not apply to these outside websites or content, or to any collection of data after you click on links to such outside websites.

Changes to This Privacy Policy

We post the effective date of this Privacy policy below. The Privacy Policy in effect at the time you use the Site governs how we may use your information. This Privacy Policy is subject to occasional revision, and if we make any substantial changes in the way we use your Personal Information, we will post the revised policy with an updated effective date and endeavor to notify you by sending you an e-mail to the last e-mail address you provided to us and/or by prominently posting notice of the changes on our website. Any material changes to this Privacy Policy will be effective upon the earlier of thirty (30) calendar days following our dispatch of an e-mail notice to you or thirty (30) calendar days following our posting of notice of the changes on our site. These changes will be effective immediately for new users of our website, products or related services. Please note that at all times you are responsible for updating your Personal Information to provide us with your most current e-mail address. In the event that the last e-mail address that you have provided us is not valid, or for any reason is not capable of delivering to you the notice described above, our dispatch of the e-mail containing such notice will nonetheless constitute effective notice of the changes described in the notice. In any event, changes to this Privacy Policy may affect our use of Personal Information that you provided us prior to our notification to you of the changes. If you do not wish to permit changes in our use of your Personal Information, you must notify us prior to the effective date of the changes that you wish to deactivate your account with us. Continued use of our website, products, or related services, following notice of such changes shall indicate your acknowledgement of such changes and agreement to be bound by the terms and conditions of such changes.

This Privacy Policy is effective as of April 1, 2016. If you have questions about this Privacy Policy, please contact the AMAG Legal Department by email at LegalDept@amagpharma.com.

Indication

Makena (hydroxyprogesterone caproate injection) is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. The effectiveness of Makena is based on improvement in the proportion of women who delivered <37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity.

Limitation of use: While there are many risk factors for preterm birth, safety and efficacy of Makena has been demonstrated only in women with a prior spontaneous singleton preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth.

Important safety information for Makena (hydroxyprogesterone caproate injection)
  • Do not use Makena in women with any of the following conditions:
    • Current or history of thrombosis or thromboembolic disorders
    • Known or suspected breast cancer, other hormone-sensitive cancer or history of these conditions
    • Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
    • Cholestatic jaundice of pregnancy
    • Liver tumors, benign or malignant, or active liver disease
    • Uncontrolled hypertension
  • Makena should be discontinued if thrombosis or thromboembolism occurs
  • Allergic reactions, including urticaria, pruritus and angioedema have been reported with use of Makena or with other products containing castor oil
  • Women receiving Makena should be monitored if they:
    • Are prediabetic or diabetic
    • Have conditions that may be affected by fluid retention, such as preeclampsia, epilepsy, cardiac or renal dysfunction
    • Have a history of clinical depression; Makena should be discontinued if depression recurs
    • Develop jaundice; consider whether benefit of use warrants continuation
    • Develop hypertension
  • Certain pregnancy-related fetal and maternal complications or events were numerically increased in Makena-treated subjects as compared to placebo subjects, including miscarriage (2.4% vs. 0%) and stillbirth (2% vs. 1.3%), admission for preterm labor (16% vs. 13.8%), preeclampsia or gestational hypertension (8.8% vs. 4.6%), gestational diabetes (5.6% vs. 4.6%), and oligohydramnios (3.6% vs. 1.3%)
  • The most common adverse reactions reported in ≥2% of subjects and at a higher rate in the Makena group than in the control group were injection site reactions (pain [35% vs. 33%], swelling [17% vs. 8%], pruritus [6% vs. 3%], and nodule [5% vs. 2%]), urticaria (12% vs. 11%), pruritus (8% vs. 6%), nausea (6% vs. 5%), and diarrhea (2% vs. 1%)

Please see full prescribing information for Makena.

Important safety information and Indication
INDICATION
IMPORTANT SAFETY INFORMATION
Top